Drug maker Moderna, Inc. (MRNA) reported Thursday that its third-quarter net income was $13 million, compared to a net loss of $3.63 billion a year ago.
Earnings per share were $0.03, compared to loss per share of $9.53 last year.
Analysts on average expected a loss of $1.90 per share for the quarter, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
Total revenue for the third quarter grew to $1.86 billion from $1.83 billion last year. The Street was looking for revenues of $1.25 billion.
Net product sales reached $1.82 billion, reflecting a 4% year-over-year increase. Spikevax sales included $1.2 billion of U.S. sales and $0.6 billion of international sales.
The company said the growth was primarily driven by higher sales in the U.S. market, following the earlier launch of the updated COVID-19 vaccine.
Looking ahead, the company continues to expect fiscal 2024 net product sales of $3.0 to $3.5 billion from its respiratory franchise.
Stéphane Bancel, Chief Executive Officer of Moderna said, "Looking into the fourth quarter and preparing for 2025, we remain focused on driving sales growth, delivering 10 product approvals over the next three years, and continuing to reduce our cost structure."
In pre-market activity on the Nasdaq, Moderna shares were gaining around 6.1 percent to trade at $54.99.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.